Halquinol Pharma Grade intended for direct compression tablets is first passed through a 0.5 mm conical mill until D90 ≤ 75 µm, because the needle-shaped crystal habit of the chlorinated quinolin-8-ol mixture produces a Carr Index above 30 and inconsistent die filling if unmilled. A representative preformulation screening ratio comprises API 25–35 wt%, microcrystalline cellulose 50–60 wt%, crospovidone 2–4 wt%, colloidal silicon dioxide 0.5–1.0 wt%, and sodium stearyl fumarate 1–2 wt%. Magnesium stearate is avoided in this system because halquinol chelates divalent magnesium and residual iron from milled stearates, producing colored metal complexes that appear as green-brown specking in the tablet core. The blend is mixed in a bin blender at 10–12 rpm for 20 ± 2 min; blending beyond 30 min increases fines, die sticking, and electrostatic charge. Compression is performed on rotary tablet presses with polished 316L stainless steel tooling, with punch and die surface roughness maintained below Ra 0.4 µm; worn tooling releases chromium and iron ions that accelerate surface darkening. Tablet hardness is held at 7–10 kp, friability below 0.5% by Ph. Eur. 2.9.7, and disintegration within 15 min in 0.1 N HCl at 37 ± 2 °C by USP <701>. Content uniformity is confirmed according to USP <905> with an acceptance value ≤ 15. The terminal 200 mg tablet is packaged in aluminium-aluminium blister to limit UV-induced discoloration; stability is assigned under ICH Q1A(R2) conditions of 25 °C / 60% RH and 40 °C / 75% RH.

Does Wet Granulation Trigger Chelation-Driven Discoloration in Halquinol Tablet Cores?

Low-moisture wet granulation is employed when API loading exceeds 40 wt% or when direct compression cannot meet content uniformity because of API segregation. Aqueous granulation is generally unsuitable because halquinol oxidizes and forms chelates with trace iron and copper present in municipal-grade water at concentrations above 0.1 ppm. A non-aqueous granulating solution of isopropanol or ethanol with polyvinylpyrrolidone 3–5 wt% is used. The dry blend contains API 35–45 wt%, lactose monohydrate 40–50 wt%, croscarmellose sodium 2–4 wt%, and colloidal silicon dioxide 0.5–1.0 wt%. Granulation is run in a high-shear mixer with impeller speed 300–400 rpm and chopper speed 1,500–2,000 rpm; endpoint is taken when impeller torque rises 15–20% above the dry-mix baseline. The wet mass is screened through 1.2 mm and dried in a fluid-bed dryer at inlet air 45–55 °C to a loss on drying of 1.0–2.0% w/w. Overdrying below 1.0% produces granule friability, capping, and lamination; underdrying above 2.0% creates a residual moisture microenvironment that accelerates hydrolysis of chlorinated quinolines. The granulate is compressed into 300 mg tablets at 8–12 kp hardness, with friability below 0.3% and disintegration within 15 min. Residual isopropanol is controlled below 5,000 ppm according to USP <467>, and elemental impurities are aligned with ICH Q3D. Metal surface contact is minimized by using polished 316L stainless steel or glass-lined high-shear bowls for batch sizes below 50 kg.

Capsule Filling Under Low Humidity and Chelate-Control Lubrication

Hard capsule filling delivers a 250 mg halquinol unit when tablet compression is rejected due to swallowing constraints. The encapsulated blend consists of API 20–30 wt%, lactose monohydrate 60–70 wt%, pregelatinized starch 5–10 wt%, crospovidone 1–3 wt%, colloidal silicon dioxide 0.5–1.0 wt%, and sodium stearyl fumarate 1–2 wt%. The filled powder is prepared to a bulk density of 0.55–0.65 g/mL and Hausner ratio 1.25–1.35; dosator-type machines show fill weight variability above ±3% if the precompaction plug hardness is below 10 N. Relative humidity is kept below 35% because moisture mediates API diffusion into the gelatin shell and increases iron-catalyzed chelate formation on the shell surface. The gelatin or HPMC capsule shell should contain less than 10 ppm total extractable iron; higher iron grades generate black-green spots within weeks under accelerated storage. Encapsulation runs on continuous motion machines at 60,000–100,000 capsules/h; automatic checkweighing rejects capsules outside ±5% of target fill weight. Dissolution is tested by USP <711> Apparatus 2 at 50 rpm in 0.1 N HCl at 37 ± 0.5 °C; a release criterion of 75% in 45 min may be applied only if justified by national monograph data, because published dissolution specifications for halquinol capsules are limited and method development should follow USP <1092>.

Dry granulation is preferred for Halquinol Pharma Grade granules filled into aluminium sachets because residual moisture above 2.0% w/w mobilises aluminium ions from the laminate foil and forms black edge staining. The ribbon-based formula comprises API 10–20 wt%, mannitol 60–75 wt%, crospovidone 3–5 wt%, colloidal silicon dioxide 0.5–1.0 wt%, and sodium stearyl fumarate 1–2 wt%. The blend is fed to a roller compactor at roll pressure 4–6 MPa, roll gap 1.5–2.0 mm, and roll speed 2–5 rpm; the resulting ribbons are milled through a 1.0 mm screen to produce granules with D50 250–400 µm. Granule density is targeted at 0.8–1.0 g/cm³, and fines below 75 µm are limited to 15% of the batch to avoid flow obstruction in the sachet filler. The granulate is filled into foil laminate sachets with moisture vapor transmission rate below 0.1 g/m²/day; each sachet contains a unit dose of 50 mg or 100 mg halquinol where such strengths are permitted by the national monograph. Flowability is assessed by Ph. Eur. 2.9.36 with angle of repose below 35°, and water content is controlled by USP <921> at not more than 2.0%.

The following screening ranges are preformulation starting points, not licensed formulas; they must be optimized by design-of-experiment against the target jurisdiction. Magnesium stearate is excluded in oral solid systems because halquinol chelates divalent cations.

Controlling Low Free Divalent Cation Load in Oral Suspensions

Oral suspension formulations containing 20 mg/mL halquinol are designed as flocculated systems rather than fully deflocculated systems because the hydrophobic API forms a dense, non-redispersible sediment when zeta potential is driven far from zero. The aqueous vehicle comprises purified water, sorbitol 10–20% w/v, microcrystalline cellulose/carboxymethylcellulose sodium 1.0–2.0% w/v, xanthan gum 0.3–0.5% w/v, sodium benzoate 0.1–0.2% w/v, and citric acid monohydrate to maintain pH 4.0–5.0. The API is dispersed as a micronized powder with D90 below 50 µm; a rotor-stator dispersion at 3,000 rpm for 15 min is followed by high-pressure homogenization at 250–350 bar. Divalent cation-containing excipients are omitted because halquinol chelates calcium, magnesium, zinc, and iron; this exclusion covers calcium carbonate, magnesium trisilicate, iron oxide pigments, and zinc salts. Disodium edetate is also avoided because it competes with halquinol for divalent metal ions and may reduce antimicrobial activity. The finished suspension is filled into amber PET bottles with child-resistant closures; viscosity is controlled at 400–800 mPa·s at 25 °C using a Brookfield viscometer spindle 2 at 60 rpm. Sedimentation volume after 24 h is specified as 0.80–0.95; redispersion is confirmed by 5 manual inversions with no residual base sediment. Preservative effectiveness is tested according to USP <51>, microbial enumeration according to USP <61>/<62>, and non-sterile oral liquid limits according to Ph. Eur. 5.1.4, which requires total aerobic microbial count not to exceed 10³ CFU/g or mL and total yeast and mold count not to exceed 10² CFU/g or mL.

When the Route Is Parenteral, Non-Aqueous Solvent Selection Determines Feasibility

Injectable presentations of Halquinol Pharma Grade are constrained by the API’s practically insoluble state in water and by its ability to chelate metal ions released from container-closure systems. A parenteral formulation is generally limited to non-aqueous vehicles such as propylene glycol, PEG 400, or a defined mixture of both; the API concentration should not exceed 50 mg/mL unless phase-solubility analysis demonstrates adequate thermodynamic stability. Water is excluded from the formulation because its addition precipitates the API and lowers the solvent system’s thermodynamic activity. The solution is filled into amber Type I glass ampoules or vials under a nitrogen overlay; bromobutyl rubber stoppers are replaced with fluoropolymer-coated closures because untreated elastomers contain zinc and calcium that form insoluble metal chelates with halquinol. Sterile filtration through a 0.22 µm membrane is required for aseptic processing; PVDF membranes are screened first because halogenated quinolines can bind to PVDF, and the filter validation must demonstrate API recovery above 95%. If terminal sterilization is not feasible due to solvent degradation, aseptic filtration in an isolator is used rather than reducing the dwell time below pharmacopoeial sterility assurance. Particulate matter is controlled by USP <788>, sterility by USP <71>, and bacterial endotoxins by USP <85>. The terminal injectable product is acceptable only in jurisdictions where national drug authorities have registered halquinol for parenteral administration; published clinical data for this specific configuration are limited, and the high solvent load must be justified by injection-site tolerance studies.

Compliance anchors for release testing are summarized in Table 2.